echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > There are new discoveries in the prediction of the efficacy of lung cancer immunotherapy; TROP-2 antibody-conjugated drugs in the treatment of triple-negative breast cancer DCR reaches 95%|Tumor News

    There are new discoveries in the prediction of the efficacy of lung cancer immunotherapy; TROP-2 antibody-conjugated drugs in the treatment of triple-negative breast cancer DCR reaches 95%|Tumor News

    • Last Update: 2021-05-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    *Only for medical professionals to read for reference 1 minute a day, give you professional "talking information" in the tumor circle! (If you need the original text of the literature, you can add the editor's WeChat yxj_oncology to obtain) Key points: Lancet: 18F-flucloclovine-PET/CT assists prostate cancer radiotherapy, prolongs the event-free survival of patients Predict the response of NSCLC patients to PD-1/PD-L1 inhibitors CCR: Features of TIL cells co-expressing CD39, CD109, and PD-1 in ovarian cancer and their impact on prognosis.
    New drug: TROP-2 ADC has positive preliminary clinical results, Dato -DXd treatment of triple-negative breast cancer with DCR up to 95% 01Lancet: 18F-flucloclovine-PET/CT assists in prostate cancer radiotherapy, prolongs event-free survival of patients A few days ago, Lancet magazine published a single-center open label phase II/III randomized controlled trial EMPIRE -1 The study believes that positron emission computed tomography (PET/CT) based on half 18F-fluciclovine is helpful to the formulation of salvage radiotherapy plans for prostate cancer and can significantly prolong the event-free survival (EFS) of patients.

    The study was published in Lancet.
    This study included 165 prostate cancer patients who could still detect prostate-specific antigen (PSA) after prostatectomy and did not find extrapelvic or skeletal metastases on routine imaging examinations (CT or MRI).
    81 and 79 patients developed follow-up rescue radiotherapy plans based on routine imaging or 18F-fluciclovine-PET/CT examination results.

    After a median follow-up of 3.
    52 years, it was found that 81 patients in the routine imaging group and 76 patients in the 18F-fluciclovine-PET/CT group received rescue radiotherapy, respectively.The median survival time of the two groups of patients was not reached; 81% of the patients in the conventional imaging group experienced biochemical or clinical recurrence or progression, or began to receive systemic treatment, while this ratio in the PET/CT group was only 20 %.

    The event-free survival time was longer in the PET/CT group.
    The 3-year EFS rate in the conventional imaging group was 63.
    0% (95% CI 49.
    0%), while the 3-year EFS rate in the PET/CT group was 75.
    5% (95%).
    CI 62.

    According to the 18F-fluciclovine-PET/CT radiotherapy program can improve the survival of patients, the 3-year EFS rate increased by 12.
    5% ​​(95%CI 4.

    Univariate analysis suggested that the risk of recurrence, progression, or more treatment in the conventional imaging group may be higher (HR 1.
    85, 95%CI 0.
    47, p=0.
    05), and multivariate analysis further confirmed this result (HR 2.
    04, 95% CI 1.
    93, p=0.

    In terms of the safety of treatment, there was no significant difference in the incidence of adverse reactions between the two groups of patients.
    The most common adverse events were frequent urination and urgency and acute diarrhea.

    18F-fluciclovine-PET/CT imaging and radiotherapy target delineation.
    Researchers pointed out that molecular imaging methods are increasingly used to guide treatment decisions and plans for prostate cancer.

    The 18F-fluciclovine used in this study is a synthetic amino acid PET/CT tracer developed by Emory University in the United States, which can be used for recurrence imaging of prostate cancer.

    This imaging method has been proved to be better than CT and MRI in the diagnosis of biochemical recurrence of prostate cancer.
    In the future, it is necessary to further explore the role of this tracer in prostate cancer radiotherapy decision-making and treatment planning. 02JTO: mIHC/IF detection of CD39+CD8+ T cells in tumors can predict the response of NSCLC patients to PD-1/PD-L1 inhibitors May 8, 2021, a new study was published in the Journal of Thoracic Oncology, content It is related to the prediction of PD-1/PD-L1 inhibitor response by CD39+CD8+T cells in the tumor of patients with non-small cell lung cancer (NSCLC).

    Screenshot of the cover page of the paper.
    In this study, the author used mass spectrometry flow cytometry (CyTOF) to obtain immunoassay results and compared a series of clinically relevant methods with them.
    These methods include: immunohistochemistry (IHC), multiple immunohistochemistry/ Immunofluorescence (mIHC/IF), and digital gene quantification technology (NanoString) gene expression detection.

    The research results show that the results of mIHC/IF quantitative detection are correlated with the results of CyTOF, while the conventional IHC and NanoString detection cannot reflect the correlation.

    In the NSCLC group, the ratio of CD39+CD8+ T cells measured by mIHC/IF can successfully distinguish PD-1/PD-L1 inhibitor responders from non-responders [Objective Response Rate (ORR) 63.
    6%, negative group 0%].

    And the predictive ability is independent of other factors, such as the proportion of total CD8+ T cells, the proportion of CD39+ lymphocytes, PD-L1 positivity, epidermal growth factor receptor mutations and so on.

    The study shows that mIHC/IF can be used as a method to evaluate the ratio of CD39+CD8+T cells and has the effect of predicting the response of NSCLC patients to PD-1/PD-L1 inhibitors.

    03CCR: Characteristics of TIL cells co-expressing CD39, CD109, and PD-1 in ovarian cancer and their impact on prognosis May 7, 2021, Clinical Cancer Research published an article on the co-expression of CD39, CD109 and PD-1 in ovarian cancer The study of tumor infiltrating lymphocytes (TIL).

    The characteristics of this type of triple-positive lymphocytes are summarized, and their influence on tumor prognosis is explained.

    Screenshot of the cover page of the paper.
    In this study, the authors evaluated the TIL phenotype, clonality, and prognostic significance of various combinations of high-grade serous ovarian cancer (HGSC).

    In the experiment, HGSC was used as the specimen during the initial period and before and after chemotherapy, and the methods of high-dimensional flow cytometry, single cell sequencing, multiple immunofluorescence and other methods were used to detect CD39, CD103, PD-1 and other immunological markers.

    The results of the study showed that CD39, CD103, and PD-1 co-expressing cells can be divided into CD8+TIL and CD4+ regulatory T cells (Tregs).

    Among them, the triple-positive CD8+TIL showed decreased diversity of T cell receptor (TCR) and expressed genes related to cell lysis and humoral immunity.

    Triple-positive Tregs have higher TCR diversity and tumor-resident phenotype.

    In terms of prognosis, triple-positive TIL has a good prognostic effect.

    T cell immunoglobulin and ITIM domain protein (TIGIT) can specifically up-regulate triple-positive CD8+ T cells.

    The study revealed the role of CD39, CD103, and PD-1 co-expressing T cells in cell lysis, humoral immunity and regulatory immune functions.

    It is confirmed that triple-positive TIL has good prognostic significance and can be used as a high-quality target for combined immunotherapy.

    04 New drug: The preliminary clinical results of TROP-2 ADC are positive.
    Dato-DXd treats triple-negative breast cancer with a DCR of 95%.
    Recently, researchers have announced for the first time an antibody-conjugated drug (ADC) targeting TROP-2, datopotamab deruxtecan (Dato-DXd).
    ), preliminary data in a phase I clinical trial for the treatment of triple-negative breast cancer (TNBC).

    Trial data showed that among the 21 evaluable TNBC patients, Dato-Dxd achieved an ORR of 43% and a disease control rate (DCR) of 95%.

    As of January 8, 2021, a total of 24 patients in the TNBC cohort of the phase I trial received at least one dose of Dato-DXd.

    Among 21 evaluable patients, the ORR of Dato-DXd reached 43% (9/21), including 5 confirmed remissions.

    The DCR observed at the same time was 95% (20/21).

    In terms of safety, 6 patients reduced their dosage due to adverse events, mainly due to stomatitis (13%) and mucosal inflammation (8%).

    33% of patients had treatment-related adverse events ≥3.

    Overall, the most common adverse events were stomatitis, nausea, fatigue, vomiting and hair loss.

    No one left the trial due to adverse events.

    No drug-related interstitial lung disease (ILD) was found.

    Reference materials: [1]Jani AB,Schreibmann E,Goyal S,et al.
    18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer(EMPIRE-1):a single centre,open- label,phase 2/3 randomised controlled trial.
    Lancet 2021;published online May 7.
    [2]Joe Yeong,Lisda Suteja,et al.
    Intra-tumoral CD39+CD8 +T cells predict response to PD-1/PD-L1 blockade in patients with NSCLC.
    Published:May 08th,2021.
    016[3]Céline M .
    Laumont,Maartje CAWouters,et al.
    Single-cell profiles and prognostic impact of tumor-infiltrating lymphocytes co-expressing CD39,CD103,and PD-1 in ovarian cancer.
    Published:May 7th,2021DOI:10.
    1158/1078-0432 .
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.